Assistant de documentation des composantes du FLIPI2 original de 2009 pour le lymphome folliculaire

État

clinical-review-pending

Version de la méthode

Federico et al. original 2009 Follicular Lymphoma International Prognostic Index 2 (FLIPI2) arithmetic, engine original-flipi2-2009-v1: one component each for completed age at diagnosis >60 years; blood hemoglobin <12 g/dL (<120 g/L); serum beta-2 microglobulin above the same issuing report's local upper limit of normal; follicular-lymphoma marrow involvement documented as present by the pretreatment bone-marrow-biopsy local pathology report; and longest diameter of the largest involved lymph node >6 cm (>60 mm). Exact age 60, hemoglobin 12 g/dL or 120 g/L, serum beta-2 microglobulin equal to its same-report local ULN, absent marrow involvement, an explicit no-involved-lymph-node state, and a largest-node diameter of exactly 6 cm or 60 mm each contribute zero. Hemoglobin and node-diameter conversions use exact factors of 10 without rounding. Serum beta-2 microglobulin and its ULN share one same-report unit, mg/L or numerically equivalent µg/mL, and are compared directly without a universal cutoff, ratio, or renal adjustment. Marrow involvement is accepted only from the verified local pretreatment bone-marrow-biopsy pathology report and is never inferred from PET, imaging, stage, or blood. The node input is an explicit no-involved-node state or the verified longest diameter of the largest involved lymph node; it is never an extranodal mass, volume, sum of diameters, or fabricated zero. All five source components from one complete initial pretreatment active-therapy assessment and all nine applicability, identity, timing, and transport confirmations are required. Output is limited to the raw 0-5 count, five component booleans, and exact entered-value audit; no group, cutoff, outcome estimate, survival or mortality estimate, probability, diagnosis, individual prognosis, treatment-start decision, disposition, recommendation, management, or care decision is supplied.

Population

Adults with histologically confirmed, newly diagnosed follicular lymphoma for whom a specialist independently selected original FLIPI2 and a compatible current disease pathway. The prospective source registered 1,093 adults at 69 European and United States institutions from January 2003 through May 2005, excluded 115 watch-and-wait patients, and assessed 942 initially treated patients: 116 receiving local treatment and 826 systemic treatment; 559/942 (59%) received rituximab. The five-variable model used 832 complete cases and had a separate 231-patient validation cohort; progression-free survival was the source endpoint. This v1 requires a previously untreated initial active-therapy context rather than observation alone; one complete pretreatment assessment; explicit blood-hemoglobin, same-report serum beta-2-microglobulin and ULN, local marrow-biopsy pathology, and nodal-state or largest-node-measurement identities; and acknowledged historical-population, classification, treatment-exposure, endpoint, and current-era transport limitations.

Limites et exclusions

Pediatric or pediatric-type disease; in-situ disease; transformed or composite disease; primary cutaneous, duodenal-type, or another site-specific entity without independently established applicability; an incompatible current disease pathway; relapse or refractory disease; post-treatment reassessment; watch-and-wait; or use to establish a diagnosis, disease subtype, pathway, source applicability, or decision to begin treatment. The 2009 source admitted WHO-2001 follicular lymphoma of any grade, so current subtype compatibility remains an independently specialist-confirmed transport judgment rather than an app-imposed grade exclusion. · Missing, unknown, inferred, imputed, defaulted, carried-forward, incomplete, mixed-timepoint, later, or post-treatment inputs; an app-inferred active-therapy context; marrow inferred from PET, imaging, Ann Arbor stage, blood, or another source; a nodal state or measurement inferred from anatomy or imaging without the required verified source record; or unverified pathology, assay, report, timing, source, identity, or unit information. · Serum beta-2 microglobulin without its same issuing report local ULN; a universal absolute cutoff, ratio, renal adjustment, different report, different unit, unsupported unit, or substituted analyte; hemoglobin with an unsupported identity or unit; marrow evidence other than the local pretreatment bone-marrow-biopsy pathology report; an extranodal mass, volume, sum of diameters, non-largest node, or fabricated zero substituted for the largest involved lymph-node state; or rounded, clamped, or altered arithmetic. · Original FLIPI; PRIMA-PI; m7-FLIPI; FLEX; FLIPI24; POD24; GELF or BNLI criteria; an EasyStage or anatomical-manikin implementation; source-defined group cutoffs; any group, risk adjective, outcome estimate, survival or mortality estimate, probability, individual prognosis, diagnostic conclusion, treatment-start decision, treatment, disposition, recommendation, management, or care decision.

• https://pubmed.ncbi.nlm.nih.gov/19652063/
• https://doi.org/10.1200/JCO.2008.21.3991
• https://doi.org/10.1016/j.annonc.2025.07.014

Outil importé de la bibliothèque PharmaTek de MDose. Aucune date de révision clinique indépendante n’est documentée dans cette version.

Bibliothèque source

PharmaTek · MDose

Version importée

4b66536936ed

État de publication

Révision clinique en cours